Jonnetta Hill, APRN
Family · Canton, OHNPI 1063964237
Payments from drug & device makers
Across 370 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$952
- Novo Nordisk$758
- Boehringer Ingelheim$559
- Abbott$504
- Pfizer$492
- plus $3K from 24 others
What the payments were for
- Food & beverage$7,308100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,135 |
| AstraZeneca | 23 | $952 |
| Novo Nordisk | 49 | $758 |
| Boehringer Ingelheim | 40 | $559 |
| Abbott | 8 | $504 |
| Pfizer | 41 | $492 |
| Biohaven Pharmaceuticals, Inc. | 25 | $380 |
| Vanda Pharmaceuticals Inc. | 18 | $342 |
| Xeris Pharmaceuticals, Inc. | 7 | $285 |
| Sanofi-aventis U.S. LLC | 13 | $284 |
| GSK | 9 | $222 |
| Teva Pharmaceuticals USA, Inc. | 12 | $211 |
| Biohaven Pharmaceutical Holding Company Ltd. | 19 | $185 |
| Lilly USA, LLC | 12 | $172 |
| Sunovion Pharmaceuticals Inc. | 9 | $137 |
| Almatica Pharma LLC | 8 | $133 |
| Corcept Therapeutics | 1 | $115 |
| Phathom Pharmaceuticals, Inc. | 1 | $107 |
| Dexcom, Inc. | 4 | $67 |
| Merck | 4 | $57 |
| Alkermes, Inc. | 2 | $40 |
| Exact Sciences | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $15 |
| Novartis | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Athena Bioscience, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$575
- FARXIGA$575
- FREESTYLE LIBRE 3$268
- GVOKE HYPOPEN$249
- SYMBICORT$198
- AIRSUPRA$155
- Mavyret$125
- Wegovy$115
- Korlym$115
- SOLIQUA 100/33$110
- NURTEC ODT$108
- AREXVY$108
- Ozempic$108
- VOQUEZNA$107
- Creon$103
How this compares
$7,308 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 93 | $107,696 |
| OzempicSemaglutide | 68 | $77,370 |
| FarxigaDapagliflozin Propanediol | 65 | $66,609 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $57,721 |
| TrulicityDulaglutide | 37 | $54,857 |
| RybelsusSemaglutide | 19 | $28,359 |
| EliquisApixaban | 17 | $21,847 |
| JanuviaSitagliptin Phosphate | 14 | $15,697 |
| XareltoRivaroxaban | 16 | $11,550 |
| TradjentaLinagliptin | 11 | $11,133 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,054 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $9,431 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 272 | $8,686 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,060 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $4,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $559 | $118,828104 claims |
| Novo NordiskOzempic, Rybelsus | $758 | $105,72987 claims |
| AstraZenecaFarxiga, Symbicort | $952 | $76,66298 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $222 | $74,21371 claims |
| Lilly USA, LLCTrulicity | $172 | $54,85737 claims |
| PfizerEliquis | $492 | $21,84717 claims |
| MerckJanuvia | $57 | $15,69714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Canton
- Brittany McClainCanton$17K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.